DFDA

Pembrolizumab (for recurrent/metastatic NPC)

Treatment for Nasopharynx Cancer

Typical Dosage: 200 mg IV every 3 weeks or 400 mg IV every 6 weeks.

Effectiveness
65%
Safety Score
45%
Clinical Trials
3
Participants
5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
200 mg IV every 3 weeks or 400 mg IV every 6 weeks.
Time to Effect
Weeks to months
Treatment Duration
Until disease progression or unacceptable toxicity (can be 1-2 years+)
Evidence Quality
MODERATE
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$170,000
Monitoring:$15,000
Side Effect Mgmt:$10,000
Total Annual:$195,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$780,000
Cost per Remission
$3,900,000
Comparison vs Gemcitabine + Cisplatin
Cost Difference
+$150,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Risk Assessment
Requires Monitoring
Yes
Needs lab work/checkups
Pembrolizumab (for recurrent/metastatic NPC) Outcomes

for Nasopharynx Cancer

Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+25%
Remission Rate
+5%
Common Side Effects
Fatigue
+40%
Nausea
+25%
Rash/Pruritus
+20%
Hypothyroidism
+15%
Diarrhea/Colitis
+7%
Pneumonitis
+3%

Sources:

oncozine.com
nih.gov
ncku.edu.tw

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
1 active trial recruiting for Pembrolizumab (for recurrent/metastatic NPC) in Nasopharynx Cancer

Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC

NCT03813394ACTIVE NOT RECRUITINGPHASE1, PHASE2
View Study
48 participants
INTERVENTIONAL
Singapore, Singapore
Started: May 1, 2019
Completed Clinical Trials
1 completed trial for Pembrolizumab (for recurrent/metastatic NPC) in Nasopharynx Cancer

Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)

NCT02611960COMPLETEDPHASE3
View Study
233 participants
INTERVENTIONAL
Started: Apr 18, 2016